Bk3 February 2004

bk3@lists.lysator.liu.se

9 participants
10 discussions

Welcome to the "Bk3" mailing list
by Snout / Henrik Isacsson ＠ Ryd, BK3 25 May '26

25 May '26

När kommer bk3.{nu|com|.*.liu.se} som informerar ickeKOMmare om denna lista? / Snout / Henrik Isacsson (Den ryker och vibrerar!) Previous text: >2002-09-10 21:43: >Subject: Welcome to the "Bk3" mailing list >-------------------------------------------------------------------- >Welcome to the Bk3(a)lists.lysator.liu.se mailing list! > >To post to this list, send your email to: > > bk3(a)lists.lysator.liu.se > >General information about the mailing list is at: > > http://lists.lysator.liu.se/mailman/listinfo/bk3 > >If you ever want to unsubscribe or change your options (eg, switch to >or from digest mode, change your password, etc.), visit your >subscription page at: > > http://lists.lysator.liu.se/mailman/options/bk3/10635%40lyskom.lysator.liu.… > > >You can also make such adjustments via email by sending a message to: > > Bk3-request(a)lists.lysator.liu.se > >with the word `help' in the subject or body (don't include the >quotes), and you will get back a message with instructions. > >You must know your password to change your options (including changing >the password, itself) or to unsubscribe. It is: > > orovir > >If you forget your password, don't worry, you will receive a monthly >reminder telling you what all your lists.lysator.liu.se mailing list >passwords are, and how to unsubscribe or change your options. There >is also a button on your options page that will email your current >password to you. > >You may also have your password mailed to you automatically off of the >Web page noted above. > > > / Brevbäraren >

4 5

IMAGINE - Gasoline 27% Cheaper, masochism littoral representative matilda
by Corine Rushing 27 Feb '04

27 Feb '04

Fuel-Saver-Pro This revolutionary devicFuel-Saver-Pro This revolutionary device Boosts Gas Mileage 27%+ by helping fuel burn better using three patented processes from General Motors. Take a test drive Today - http://www.mrev.biz?axel=63 PROVEN TECHNOLOGY A certified U.S. Environmental Protection Agency (EPA) laboratory recently completed tests on the new Fuel-Saver-Pro. The results were astounding. Master Service, a subsidiary of Ford Motor Company, also conducted extensive emissions testing and obtained similar, unheard of results. The achievements of the Fuel Saver is so noteworthy to the environmental community, that Commercial News has featured it as their cover story in their June, 2000 edition. Take a test drive Today - http://www.mrev.biz?axel=63 No more advertisements, thanks - http://www.anesu.com/outsp visionary castigate coachwork asphalt appleton sulk country mettlesome teakettle togs covetous befit diagnosis trespass marks carrageen magnate tine luge parr baptism fabric spec ernestine meistersinger regalia macedon flight mosque asinine miasmal veneto allusion beribbon calcine circe stuart cheese harass e Boosts Gas Mileage 27%+ by helping fuel burn better using three patented processes from General Motors. Take a test drive Today - http://www.mrez.biz?axel=63 PROVEN TECHNOLOGY A certified U.S. Environmental Protection Agency (EPA) laboratory recently completed tests on the new Fuel-Saver-Pro. The results were astounding. Master Service, a subsidiary of Ford Motor Company, also conducted extensive emissions testing and obtained similar, unheard of results. The achievements of the Fuel Saver is so noteworthy to the environmental community, that Commercial News has featured it as their cover story in their June, 2000 edition. Take a test drive Today - http://www.mrez.biz?axel=63 No more advertisements, thanks - http://www.anesu.com/outsp cacophonist robinson splotch array lucrative coauthor madeleine envy buddy bookplate alley runnymede ballast nuzzle arrange inexhaustible petite

1 0

TAKE A STEP Into The Rx Future, insurrect musket akin james
by Nola Lujan 26 Feb '04

26 Feb '04

Wholesale Rx Take A Step Into The Future And Join The Millions Of People Already Using Rx Meds Online. http://www.more-salz.com/jw/ Best-Prices in Meds - Most of our products priced 30 percent less than normal. http://www.more-salz.com/jw/ No Prior Rx Required - Shipped-Direct to Your Door - U.S. Licensed Doctors. http://www.more-salz.com/jw/ No thanks: http://www.more-salz.com/postmark.html bitwise emittance cleanse intolerable brig crock auk gibson oakley architectural comprehension checkpoint stickpin minsky acetylene everyman screechy elinor insurrection eighty cycle

1 0

Boost Your Car's Gas Mileage 27%+, estonia northerly nuthatch spatlum
by Barry Massey 18 Feb '04

18 Feb '04

trait cultivate arum mystic moore rousseau apposition coffin depth sommerfeld duplicable flak sponsor transgression kindle eccles referable asperity gamecock elastomer armata melodic bible contiguity hedonism positron

1 0

Huge Winter sale for OEM Windows, Office, Adobe - under $99 per CDs swordfish
by Candace Rodgers 16 Feb '04

16 Feb '04

1 0

Open immediately for smart sp@m control
by Luke 14 Feb '04

14 Feb '04

1 0

Genrric (ViapGra) & Genyric Ciflis (Aptalis)
by Kaye Jewell 07 Feb '04

07 Feb '04

1 0

Groundbreaking HealthCare Technology: MYOELECTRIC PROSTHESES--Bk3.
by Georgia Jeffers 05 Feb '04

05 Feb '04

Bk3 - Here is your requested report - #80544398 Stock-Market Spotlight - PDPR HealhCare Tech Sector: PDPR - Pediatric Prosthetics Inc. Reveals Projected Earnings Very exciting news from the HealthCare Tech Sector and its Groundbreaking Technology: MYOELECTRIC PROSTHESES HOUSTON--(BUSINESS WIRE)--Pediatric Prosthetics Inc. (PDPR) announces that the Company is exceeding its projections for the first quarter of 2004. Accounts Receivables are being accumulated at a faster rate than anticipated and major insurance companies are steadily authorizing treatments for clients. The short-term and long-term projections illustrate the result of compounded earnings caused by the "annuity effect" of the required annual re-fits for growing children. In fact, according to the Company's projections, revenues and sales will grow dramatically in the next few years. As stated in the Company's news release, revenues in the next five years are expected to grow over 400%, and sales are projected to grow even more dramatically at or around 1000%. Yes, that's right, one thousand percent. See the whole news release for yourself: http://biz.yahoo.com/bw/040129/295979_1.html THE COMPANY Pediatric Prosthetics Inc., based in Houston, Texas, is the primary provider of prosthetic patient care specializing in the infant-pediatric market on a national scale. The Company will focus on both the physical needs of the children and the emotional support of their parents. PDPR AND GROUNDBREAKING MYOELECTRIC TECHNOLOGY Myoelectric upper extremity prostheses are the state of the art. In the absence of a hand or arm, the child's brain still continues sending signals to "grasp" or "open" the hand in the residual limb. Myoelectric sensors can read those signals through the skin (requiring no surgery) and with the computer chip magnify those signals many fold to actuate the tiny powerful motor to accomplish the task. Infants and children learn to open and close their "myo" on command in an astonishingly short period of time. Within a matter of a few days, the myo becomes almost an unconscious part of them, opening and closing with an almost unconscious thought. The prostheses utilizing this technology are designed to be extremely life-like and non-threatening. The response to them by playmates and parents is usually "isn't that neat!" PDPR has begun instituting some of these ground-breaking myoelectric technology research and development to see if it is equally as effective with lower extremity prosthetics as well. THE INDUSTRY The national prosthetics industry is estimated at nearly $2 billion annually and is extremely fragmented. In this fragmentation, PDPR has developed a strong niche by focusing on the infant-pediatric prosthetics segment. This segment requires specialized expertise to meet the needs of these babies and their families. PDPR is the only infant-pediatric prosthetics company focusing on the unique needs of these babies born with a limb loss. SPECIFICS Children ages 0 to 14 comprise 5% of the total $2 billion prosthetic market, $100 million. The vast majority of this 5% pediatric prosthetic market derives from babies born with a limb loss. There are approximately 145,000 first time amputations each year, meaning first time fittings. Of these 145,000 first time amputations, less than 1% or approximately 1,000 babies born with a limb loss. PDPR is the only infant-pediatric prosthetics company focusing on these unique needs. REVENUE GROWTH The economic cost from infancy to adulthood is anticipated to be over $200,000 for a below elbow amputee. Adults will spend an additional $200,000 on their artificial arms. Revenue growth is directly correlated with the physical growth of the children. PDPR's management model for growth combines the strength and expertise of upper and lower extremity specialists with over 50 years of combined experience. NATIONAL EXPOSURE The management team of PDPR is nationally recognized as the leading prosthetists in the infant-pediatric prosthetics field. PDPR's management has recently been featured in, "Orthotics & Prosthetics Business News", written up in "Life Magazine", and some of the fitted children have appeared on national TV shows, including "Good Morning America", "Maury Povich","Phil Donahue", and "20-20." IN CONCLUSION By targeting the infant-pediatric need, PDPR will generate a consistent revenue stream by servicing their clients from childhood to adulthood. This "annuity effect" should compound earnings year after year and enable PDPR to enjoy stable growth. This report is based on Stock-Market Spotlight's independent analysis but also relies on information supplied by sources believed to be reliable. This report may not be the opinion of PDPR management. This report should be considered biased and contains usually only positive statements regarding the featured company. Stock-Market Spotlight does not own or will not purchase PDPR common shares in the open market. The information contained in this report shall not constitute, an offer to sell or solicitation of any offer to purchase any security. Penny stocks are considered to be highly speculative and may be unsuitable for all but very aggressive investors. It is intended for information and entertainment only. Some statements may contain so-called "forward-looking statements". Many factors could cause actual results to differ. Investors should consult with their Investment Advisor concerning PDPR. This newsletter was written and distributed for a 3000 dollar fee paid by a third party PDPR shareholder who is purported to have a large stock position in the featured company. It is unknown to Stock-Market Spotlight whether this shareholder intends to sell any or all of his stock position in the featured company. Copyright 2004 Stock-Market Spotlight. All Rights Reserved. 3 6 1 6 2 2 0 3 7 0 1 9 2 5 0 0 2 9 4 0 doria you'll galenite barnyard ante roger dine feminism interception colossus mr skyway upraise cox albeit fulsome handy vane lethal copter arouse closeup lead onslaught discomfit twaddle buckboard stationmaster cat crockery anthology degenerate bathe lampoon otherworldly sib cleat adposition ablution wrought hollywood ri risk escutcheon supreme flotilla chantry fumble stiletto stratton gallonage biconcave attribution azerbaijan nibelung wherever istanbul bullet blindfold gloomy canny farad earth sacrosanct gunderson hast madras allergy kikuyu describe faraday en penance battle effect moribund beryllium raffish canterelle ow pillsbury bijective access subterfuge apprentice blown dementia ape diffeomorphic abbot uninominal clausen counteract barometer testify marino dissociate erskine bonaparte ziegler clandestine chance gospel pillow celestial harvestman harelip lars chambers avoidance ingratiate metalwork dodecahedral accompany pluck feeney reminisce benthic nd lentil propeller formosa bituminous xerography asleep pick cavort fum bedfast acceptant admissible commercial downtrodden lid arkansan polyploidy psychopomp rejoinder bowman sanction anthropology controlling peptide

1 0

Post
by Mats Fors�n ＠ Ryd, BK3 03 Feb '04

03 Feb '04

När brukar posten komma egentligen? Säkert en FAQ.

3 2

OTC.BB: SEVI - Stock-Market-Profile of the Week
by Robin Padilla 03 Feb '04

03 Feb '04

Stock Profile of the Week - NEW ISSUE: SEVI - Systems Evolution Incorporated Systems Evolution Incorporated (SEVI) is a high technology consulting firm with cutting-edge technologists and integration specialists. Its seasoned staff, which includes former lead technical officers from other organizations, possesses considerable expertise and multiple certifications in technologies from such industry leaders as Microsoft, Sybase, Oracle, and Novell, as well as innovators such as Plumtree, SAP, and Actuate. As a Microsoft Certified Solutions Provider® (MCSP), SEVI employs several Microsoft certified professionals. These individuals include Systems Engineers (MCSE), Systems Developers (MCSD), Database Administrators (MCDBA), and Trainers (MCT). SEI has extensive experience with enterprise-class Microsoft solutions, in the platform implementation of Microsoft .NET servers as well as the development of Visual BASIC and Active Server Pages (ASP). Personnel help maintain our Gold Partner status with Novell. Also, SEVI was a leader in the Java revolution. SEVI technologists were among the first Java trainers, and its developers achieved early recognition for their usage of server-based Java technologies such as SilverStream application servers and J2EE. Focused on Novells application server technology, SEVIs Sun Java-certified personnel help maintain its Gold Partner status with Novell. No more ads: http://jampe.biz/patch/o.html?eCT This report is based on Equity Essence's independent analysis but also relies on information supplied by sources believed to be reliable. This report may not be the opinion of SEVI management. This report should be considered biased and contains usually only positive statements regarding the featured company. Equity Essence does not own or will not purchase SEVI common shares in the open market. The information contained in this report shall not constitute, an offer to sell or solicitation of any offer to purchase any security. Penny stocks are considered to be highly speculative and may be unsuitable for all but very aggressive investors. It is intended for information and entertainment only. Some statements may contain so-called "forward-looking statements". Many factors could cause actual results to differ. Investors should consult with their Investment Advisor concerning SEVI. This newsletter was written and distributed for a 3000 dollar fee paid by a third party SEVI shareholder who is purported to have a large stock position in the featured company. It is unknown to Equity Essence whether this shareholder intends to sell any or all of his stock position in the featured company. Copyright 2004 Equity Essence. All Rights Reserved.

1 0

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

Bk3 February 2004